A Rolling Stone article by Andrew Perez cited Fred Ledley’s INET working paper on the NIH seed funding of pharmaceuticals.
“Republicans rely on the wrong data to try to justify repealing Biden’s Medicare drug negotiation plan.”
…
“According to a recent RAND Corporation study, drug companies charge 278 percent higher prices for medicines in the United States than in other wealthy countries. The primary reason for this is that Congress for decades barred Medicare from negotiating drug prices, something virtually all other countries. Adding insult to injury, the U.S. government helps fund research and development on all drugs that are approved for sale.”
